

EBCC

European
Breast Cancer
Conference

8

21-24 March 2012

VIENNA
AUSTRIA

ADVANCE PROGRAMME
& CALL FOR ABSTRACTS



www.ecco-org.eu



Save the Dates

Registration

Early Rate Registration Closes (<i>receipt of payment</i>)	24 October 2011
Regular Rate Registration Closes (<i>receipt of payment</i>)	13 February 2012
Late Rate Registration Closes (<i>receipt of payment</i>)	20 March 2012

Abstract Submission

Regular Abstract Submission Opens	01 September 2011
Regular Abstract Submission Closes	15 November 2011
Fellowship Grant Application Closes	15 November 2011
Late Breaking Abstract Submission Opens	01 February 2012
Late Breaking Abstract Submission Closes	15 February 2012
Housing Reservation Closes	17 February 2012

Conference Secretariat & Venue

Conference Secretariat

c/o ECCO - the European CanCer Organisation
Avenue E. Mounier 83
B-1200 Brussels
Tel: +32 (0)2 775 02 01
Fax: +32 (0)2 775 02 00
e-mail: ebcc8@eccoorg.eu
www.ecco-org.eu

Conference Venue

Austria Center Vienna (ACV)
Bruno-Kreisky-Platz 1
A-1220 Vienna
Tel: +43 (0)1 260 69 0
Fax: +43 (0)1 260 69 303
e-mail: office@acv.at
www.acv.at

Exhibition & Sponsorship

The EBCC-8 Conference Exhibition represents an essential and integral element of the Conference, providing participants with an excellent platform for networking as well as perfect opportunity to gain further insight into cutting edge technology, latest healthcare solutions and services within the oncology field.

For information about sponsorship and exhibition opportunities please contact:
Bruno De Man directly via e-mail: bruno.deman@ecco-org.eu, or Tel: +32 (0)2 775 02 04.
To download the Invitation to Industry brochure and view the exhibition floor plan please visit the ECCO website at: www.ecco-org.eu.



Accreditation for Continuous Medical Education (CME)

Application for accreditation has been submitted to the Accreditation Council of Oncology in Europe (ACOE).

Table of Contents

Letter of Welcome	3
Organising Partners	4
Conference Committees	5
Scientific Programme	6
■ Programme at a Glance	6
■ Format of Sessions	7
■ Workshop Programme	8
■ Detailed Advance Programme	12
Call for Abstracts	20
■ Abstract Policies and Regulations	21
■ Abstract Preparation and Submission	22
■ Abstract Submission Procedure	23
■ Abstract Selection Process	23
■ Abstract Categories	24
■ Abstract Policy and Regulations	25
■ Embargo Policy	27
Fellowships & Educational Awards	28
The European Breast Cancer Arts and Humanities Award	30
Registration	31
Registration Form	32
General Information	33
Social Event	35
Accommodation & Local Services	36
Hotel Registration Form	37

Letter of Welcome

It is our great pleasure to welcome you to Vienna, Austria, for the eighth European Breast Cancer Conference. As part of a biennial series of pioneering meetings, EBCC-8 is devoted to presenting, educating on, and debating the most up-to-date developments, topics and ideas within the field of breast cancer. Our goals, as ever, are to continue advancing the rapid translation of clinical research into practice; encourage the integration and coordinated organisation of treatment modalities; and to bring together patient representatives, clinicians, health professionals and scientists to continue working together towards delivering equal access and optimal care for breast cancer patients.

We are excited about the Scientific Programme for EBCC-8. Topical discussions on the biology of metastatic breast cancer will improve our understanding of the process of metastasis and enable progressive disease management; key emphasis is also being placed on areas of considerable concern such as barriers to clinical research and the management of both young and elderly patients. There will also be focussed workshops on radiotherapy, surgery, screening and consensus guidelines from our partner societies. The tradition of high quality Oxford-style debates on important controversies is being continued, and the EUROPA DONNA sessions will help to put all the new data into perspective – i.e. what it means for the patient.

The exceptional standards of the keynote symposia, teaching lectures, clinical symposia, debate sessions and outstanding speakers are now being enhanced by a new feature: 'Patient Day' which will enable the lay public to talk to experts at local and international level about breast cancer concerns. This encompassing approach will enable EBCC-8 participants to truly focus on the holistic picture of breast cancer, including research, prevention, treatment, advocacy and care.

Our host city assuredly matches the exciting promise of the conference itself. Speakers, participants, guests and friends can all expect to be enchanted by Vienna, the city of the Habsburgs, Beethoven, Mozart, Strauss and Freud. Characterised not only by undeniable imperial grandeur, stately architecture and the famous 'blue' Danube, it is arguably one of Europe's most cosmopolitan cities with cutting-edge artistry. Vienna has something for everyone, whatever your age, taste or interest. We believe that the social and cultural events will measure up to the high scientific value of the Conference itself. We look forward to welcoming you during 21- 24 March 2012 in the confidence that it will be a truly memorable experience. Thank you for joining us in Vienna to mark the next EBCC milestone towards ultimately curing breast cancer.

David Cameron (UK)
Chair

Elisabeth Bergsten Nordström (SE)
Co-chair

Michael Gnant (AT)
Chair, National
Organising Committee

Organising Partners

Inaugurated in 1998, the biennial series of European Breast Cancer Conferences (**EBCCs**) are jointly organised by **EUROPA DONNA** (the European Breast Cancer Coalition), the **EORTC Breast Cancer Group** (the European Organisation for Research and Treatment of Cancer), and **EUSOMA** (European Society of Breast Cancer Specialists):



EUROPA DONNA – The European Breast Cancer Coalition is an independent, non-profit organisation whose members are affiliated groups from throughout Europe. The coalition works to raise awareness of breast cancer and to mobilise the support of European women in pressing for improved breast cancer education, appropriate screening, optimal treatment and care and increased funding for research. EUROPA DONNA represents the interests of European women regarding breast cancer to local and national authorities as well as to institutions of the European Union.

For additional information on EUROPA DONNA please visit:
www.europadonna.org



The **EORTC Breast Cancer Group** is a multidisciplinary group of clinical researchers and scientists involved in the development, coordination and implementation of clinical and translational research, endeavouring to improve treatment of breast cancer patients in Europe and beyond.


For additional information on the EORTC Breast Cancer Group please visit:
www.eortc.eu



EUSOMA is a multidisciplinary association whose main role is to unify and publicise the results of scientific research and increase contacts between basic scientists and clinicians in order to facilitate the passage of information from the experimental stage to state-of-the-art treatments.

For additional information on EUSOMA please visit: www.eusoma.org

The European Breast Cancer Conferences are the responsibility of the not-for-profit association 'Breast Cancer Working Group' (BCWG-vzw).



The European Breast Cancer Conferences are coordinated by ECCO – the European CanCer Organisation.

ORGANISING COMMITTEE

D. Cameron (United Kingdom) **Conference Chair**
 E. Bergsten-Nordström (Sweden) **Conference Co-Chair**
 M. Gnant (Austria) **National Organising Committee Chair**
 A. Fourquet (France)
 M. Piccart (Belgium)
 E. Rutgers (The Netherlands)
 G. Viale (Italy)

PROGRAMME COMMITTEES

EXECUTIVE SCIENTIFIC COMMITTEE

D. Cameron (United Kingdom) **Conference Chair**
 E. Bergsten-Nordström (Sweden) **Conference Co-Chair**
 B. Borisch (Switzerland)
 A. Di Leo (Italy)
 M. Dixon (United Kingdom)
 J. Foubert (Belgium)
 A. Fourquet (France)
 M. Gnant (Austria)
 L. Holmberg (Sweden)
 I. Kunkler (United Kingdom)
 S. Loibl (Germany)
 M. Piccart (Belgium)
 E. Rutgers (The Netherlands)
 P. Skaane (Norway)
 T. Sørli (Norway)
 F. Symmans (USA)
 M. van de Vijver (The Netherlands)
 S. Verma (USA)
 G. Viale (Italy)

SCIENTIFIC ADVISORY COMMITTEE

REPRESENTATIVES EUROPA DONNA

G. Abela (Malta)
 A. Bonifacino (Italy)
 S. Erdem (Turkey)
 I. Kössler (Sweden)
 G. Mastruk (Ukraine)
 M. Miklavčič (Slovenia)
 A. Scharpantgen (Luxembourg)
 E. Tomberg (Estonia)
 E. Verschuur (The Netherlands)
 N. Zernik (France)

REPRESENTATIVES EORTC – BCG

S. Bianchi (Italy)
 H. Bonnefoi (France)
 E. Brain (France)
 F. Cardoso (Portugal)
 L. Cataliotti (Italy)
 T. Cufer (Slovenia)
 R. Iggo (France)
 J. Jassem (Poland)
 J. van der Hage (The Netherlands)
 H. Westenberg (The Netherlands)

REPRESENTATIVES EUSOMA

U. Bick (Germany)
 M. Castiglione (Switzerland)
 E. Gustafsson (Sweden)
 T. Kuhn (Germany)
 F. Macneill (United Kingdom)
 A. Ponti (Italy)
 P. Regitnig (Austria)
 F. Sardanelli (Italy)
 C. van Asperen (The Netherlands)
 E. Van Limbergen (Belgium)

REPRESENTATIVES FROM ASIA/AUSTRALIA

B. Chua (Australia)
 M. Toi (Japan)
 F. Boyle (Australia)
 M. Bhattacharya (India)
 J. Chen (China)

NATIONAL ORGANISING COMMITTEE

M. Gnant (Vienna) **Chair**
 R. Bartsch (Linz)
 P. Dubsy (Vienna)
 M. Filipits (Vienna)
 F. Fitzal (Vienna)
 S. Eisenburger (Vienna)
 R. Greil (Salzburg)
 E. Handl-Zeller (Vienna)
 T. Helbich (Vienna)
 R. Jakesz (Vienna)
 M. Knauer (Feldkirch)
 C. Marth (Innsbruck)
 C. Singer (Vienna)
 G. Steger (Vienna)
 C. Zielinski (Vienna)

Programme at a Glance

TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY
20 March 2012	21 March 2012	22 March 2012	23 March 2012	24 March 2012
	08:30 - 13:00 EBCC-8 Partners Workshops	08:00 - 08:45 Teaching Lectures EUROPA DONNA Teaching Lecture		Lay Public Programme Further information to be announced
		09:00 - 10:00 Patient Management Workshops Challenge the Expert		
		10:00 - 16:30 Exhibition	10:00 - 14:00 Exhibition	
		10:30 - 11:30 Patient Management Workshops Challenge the Expert		
		11:45 - 12:45 Debates		
12:00 - 15:00 Registration (groups only)	12:00 - 13:30 Welcome Lunch and Poster Viewing	12:45 - 14:00 Lunch and Poster Viewing		
	12:00 - 18:30 Exhibition			
15:00 - 18:00 Registration (individuals and groups)	13:30 - 15:30 Opening Symposium	14:00 - 15:30 Keynote Symposium		
	16:00 - 18:30 Clinical Science Symposia Debates EUROPA DONNA Sessions	16:00 - 18:30 Clinical Science Symposia Debates EUROPA DONNA Sessions	16:00 - 17:30 Satellite Symposia	
		18:30 - 20:00 Satellite Symposia		
		18:30 - 20:00 Satellite Symposia		

Format of Sessions

CHALLENGE THE EXPERT

Interactive session where the moderator will present a case based presentation, followed by an open discussion between the audience and experts.

CLINICAL SCIENCE SYMPOSIA

Clinical Science Symposia will include invited speaker presentations as well as selected oral presentations (to be selected in January 2012).

DEBATES

The format of the Oxford union-style debate allows for two persons proposing a resolution and two persons opposing it. Each individual will be flanked by a 'seconders'.

EUROPA DONNA WRAP UP SESSIONS

A short summary of each Clinical Science Symposium will be presented.

KEYNOTE SYMPOSIA

These sessions focus on the latest perspectives of basic research and clinical treatment in breast cancer.

LATE BREAKING ABSTRACTS AND BEST ABSTRACTS

This session will include the latest breakthrough research papers and important abstracts presented at previous Conferences.

PATIENT MANAGEMENT WORKSHOPS

The Patient Management Workshop is an interactive session coordinated by 2 coordinators presenting one clinical case linked to the Teaching Lecture topic. Management options will be discussed for this topic and there will be interaction and discussion with the audience.

POSTER DISCUSSIONS

A number of selected posters will be highlighted and placed in the appropriate context, based on the strength of the evidence. The conclusions will be critically discussed in terms of their applicability to clinical practice.

TEACHING LECTURES

Teaching Lectures are a combination of a didactic state-of-the-art lecture by a recognised expert in the field and interactive discussion with the audience.



Advanced Breast Cancer Workshop

Can an International Consensus Meeting Change the Future of Metastatic Breast Cancer Patients? Highlights From ABC1 Consensus Meeting

09:00 - 12:00

Chair: F. Cardoso (Portugal)

Chair: A. Costa (Italy)

- **ABC1 - Aims and Challenges**
Speaker: A. Costa (Italy)
- **Highlights from ABC1 - Metastatic Process: What do we Know?**
Speaker: R. Gomis (Spain)
- **Highlights from ABC1 HER2+ Breast Cancer**
Speaker: I. Krop (USA)
- **Highlights from ABC1 - Triple Negative Breast Cancer**
Speaker: E. Winer (USA)
- **Highlights from ABC1 - ER+ Breast Cancer**
Speaker: N. Harbeck (Germany)
- **Management Guidelines for Advanced Breast Cancer - Summary from ABC1**
Speaker: F. Cardoso (Portugal)
- **Questions and Discussion**



European Group for Breast Cancer Screening workshop

Current Issues in Breast Cancer Screening

08:30 - 12:45

Session One - The Benefits and Risks of Screening Mammography - A Debate

Chair: M. Rosselli del Turco (Italy)

Chair: F. Gilbert (United Kingdom)

- **Introduction**
Speaker: M. Rosselli del Turco (Italy)
- **Update on the Evidence for Breast Cancer Screening 50 - 70**
Speaker: L. Nystrom (Sweden)
- **Evidence for Screening Woman Under 50 and Over 70?**
Speaker: H.J. de Koning (The Netherlands)
- **The Adverse Effects of Screening - An Overview**
Speaker: E. Paci (Italy)
- **A Randomised Trial in One Million UK Women to Assess the Benefits of Adding One Extra Breast Screening Visit**
Speaker: R. Peto (United Kingdom)
- **Discussion Panel - For Whom is Breast Screening Effective?**
R. Peto, H. de Koning, L. Nystrom, E. Paci
- **Coffee Break**

Session Two - Screening Higher-Risk Groups?

Chair: R. Wilson (United Kingdom)

Chair: M. Rosselli del Turco (Italy)

- **Pathological Risk Factors and Screening**
Speaker: A. Vincent-Salomon (France)
- **The Evidence for Mammography Screening After Breast Cancer Treatment? - Health Technology Assessment**
Speaker: F. Gilbert (United Kingdom)
- **Effective Use of MRI in Screening**
Speaker: R. Mann (The Netherlands)
- **Evidence Based Higher Risk Screening - Who, When and How?**
Speaker: L. Holmberg (United Kingdom)
- **Discussion panel - Achieving Effective Higher Risk Screening?**
F. Gilbert, L. Holmberg, A. Vincent-Salomon, R. Mann



European Society of
Surgical Oncology

**Controversial Issues in the
Surgical Management of the
Elderly Breast Cancer Patient**

08:30 - 12:30

- **Introduction**
Coordinator:
C.J.H. van de Velde (The Netherlands)

The Breast

- **Patterns of Care in the Surgical Management**
Speaker: E. Bastiaannet (The Netherlands)
- **Competing Risks and Benefits of Additional Treatments**
Speaker: C. Markopoulos (Greece)
- **Sentinel Node Removal is All You Need in Node Positive Breast Cancer**
Speaker: L. Cataliotti (Italy)
- **Margins and Surgical Implications**
Speaker: G. Viale (Italy)
- **Tailoring DCIS Treatment**
Speaker: M. Leidenius (Finland)
- **Debate**
Radiotherapy is Standard Part of Breast Conservation Treatment
Speaker: I. Kunkler (United Kingdom)
- **Selective Surgery Alone in Breast Cancer Treatment**
Speaker: G. Liefers (The Netherlands)
- **Coffee Break**

The Axilla

- **Hormonal Therapy and Surgical Implications**
Speaker: R. Jakesz (Austria)
- **Surgery or Radiotherapy in Node Positive Breast Cancer**
Speaker: E.J.T. Rutgers (The Netherlands)
- **Putting Elderly Breast Cancer Treatment in Perspective**
Speaker: R.A. Audisio (United Kingdom)
- **General Discussion**
Coordinator:
C.J.H. van de Velde (The Netherlands)



European Society for Therapeutic
Radiology and Oncology Workshop

**What is Hot in Breast Cancer
Radiation Oncology in 2012?**

08:30 - 12:30

Target Group

The workshop is targeted at both young (including trainees) and experienced radiation oncologists, as well as other interested parties, who need an updated overview of two of the most actual clinical topics of importance in the daily practice of state of the art radiotherapy in breast cancer.

Course Aim

To cover two distinct aspects of Breast Cancer Radiotherapy, one concerning an actualisation of the highly-debated issue position of (accelerated) partial breast irradiation in routine clinical practice and one concerning the use of modern radiotherapy techniques to decrease early and late toxicity. The course will attempt to arrive at guidelines and agreements, also based on active interaction between the faculty and the audience.

Programme

Welcome to Vienna and Introduction

P. Poortmans (The Netherlands)
R. Orecchia (Italy)

Session One - Partial Breast Irradiation

Chair: P. Poortmans (The Netherlands)

- **Why Do We Need It?**
Making the Case For APBI
Speaker: B. Offersen (Denmark)
- **Overview of the Techniques - External Beam and IORT**
Speaker: R. Orecchia (Italy)

- **Overview of the Techniques - Different Brachytherapy Solutions**
Speaker: O. Ott (Germany)
- **Discussion and Summary**
Speaker: P. Poortmans
(The Netherlands)

■ **Coffee Break**

Session Two - Modern Radiotherapy Techniques

Chair: R. Orecchia (Italy)

- **Why Do We Need Them? The Ugly Truth From the Past**
Speaker: E. Senkus-Konefka (Poland)
- **Target Volume Delineation and Selection**
Speaker: P. Poortmans
(The Netherlands)
- **IMRT, IGRT and Gating**
Speaker: Y. Belkacemi (France)
- **Discussion and Summary**
Speaker: R. Orecchia (Italy)



Flims Alumni Club Workshop

**Advanced breast cancer –
current developments in
the multidisciplinary approach**

09:00 - 12:00

Chair: M. Hutka (United Kingdom)

Chair: J. van der Vorst (The Netherlands)

- **Management of triple negative breast cancer**
Speaker: M. Hutka (United Kingdom)
- **Discussion**

- **Anti-HER2 treatment in metastatic breast cancer- trastuzumab and beyond**
Speaker: E. de Azambuja (Belgium)
Discussion
- **Near-infrared fluorescence image-guided surgery in breast cancer patients**
Speaker: J. van der Vorst, (The Netherlands)
Discussion
- **Coffee Break**
- **Presentation of a Flims study**
Speaker: To be announced
Discussion
- **Role of radiotherapy in advanced breast cancer**
Speaker: O.Matzinger (Switzerland)
Discussion
- **Role of PARP inhibitors in triple negative advanced breast cancer**
Speaker: T. Yap (United Kingdom)
Discussion
- **Closing remarks**



SenoNetwork meeting

Breast Units: The Need for
a Structured Network

08:30 - 12:45

- **Revisiting the Concept of Breast Unit - Considerations 12 Years After the First EUSOMA Position Paper**
Speaker: L. Cataliotti (Italy)
Discussion

Chair: R.E. Mansel (United Kingdom)

Round Table - Major Challenges in the Breast Unit Daily Activity

- **Integrating the Diagnostic Procedures**
Speaker: R. Wilson (United Kingdom)
- **The Era of Oncoplastic Approach**
Speaker: R.E. Mansel (United Kingdom)
- **Examination of Sentinel Node**
Speaker: C. Wells (United Kingdom)
- **Data Monitoring and Medical Audit in a Breast Unit**
Speaker: P. Van Dam (Belgium)
- **Radiotherapy**
Speaker: H. Marsiglia (France)

Coffee Break

Round Table - Some of the Major Unresolved Issues in Most Breast Units

- **How to do Proper Genetic Counselling**
Speaker: O. Pagani (Switzerland)
- **How to Improve the Specialist Breast Nurse Role**
Speaker: E. Gustafsson (Sweden)
- **How to Run the Advanced Breast Cancer Clinics**
Speaker: O. Pagani (Switzerland)
- **How to Become a Certified Breast Unit**
Speaker: L. Marotti (Italy)
- **SenoNetwork, Expanding Frontiers**
Speaker: C.A. Garcia Etienne (Italy)
- **Closing Remarks**
Speaker: M. Rosselli del Turco (Italy)

Detailed Advance Programme

WEDNESDAY 21 MARCH 2012

Poster Viewing 12.00-13.30

Opening Symposium 13.30-15.30

Welcome Address

Conference Chair

D.A. Cameron (United Kingdom)

Conference Co-Chair

E. Bergsten-Nordstrom (Sweden)

Chair National Organising Committee

M. Gnant (Austria)

The European Breast Cancer Arts and Humanities Award

Awarded to the individual who has 'made a difference' through an artistic or humanistic activity such as: artwork, dance, film, literature, music, photography or poetry and whose contribution and personal achievements reflect the efforts and vision that unites EBCC.

Chair: E. Bergsten-Nordstrom (Sweden)

The European Breast Cancer Science Award Emmanuel van der Schueren Lecture

■ What the Past is Telling Us About the Future

Award Lecturer: A. Costa (Italy)

■ The EBCTCG Oxford Overview, 1984-2012

Keynote Lecturer: R. Peto (United Kingdom)

■ The Biology of Breast Cancer - The New Super Highway to the Clinic

Keynote Lecturer: C.M. Perou (USA)

Clinical Science Symposia 16.00-17.30

Neo-adjuvant Therapy in Breast Cancer

Neo-adjuvant chemotherapy is now widely accepted as a standard of care for many patients with large operable, or locally advanced tumours. However, there remain many questions, including use of other agents, optimal chemotherapy, post-chemotherapy pathological assessment and local management. In addition, the validity of pathological complete response rate as a surrogate for outcome of the same treatment in the adjuvant setting remains unclear.

Chair: F. Symmans (USA)

Chair: G. von Minckwitz (Germany)

■ Pathology of Neo-adjuvant Chemotherapy in Breast Cancer

Speaker: F. Symmans (USA)

■ Neo-adjuvant Therapy: What, When and Why

Speaker: I. Smith (United Kingdom)

■ Local Treatment

Speaker: M.J. Vrancken - Peeters (The Netherlands)

Resistance to Hormonal Therapy

Endocrine agents remain the most widely used class of drugs in the treatment of breast cancer. Despite many years of research, we still don't know how to overcome all the resistance that emerges in the clinic to this class of agents, and this session will present up-to-date data on the progress being made in this area.

Chair: J. Baselga (USA)

Chair: R. Greil (Austria)

- **Overview of Mechanism of Resistance in Hormonal Therapy**
Speaker: L. Malorni (Italy)
- **Modulation of Resistance to Biological Agents**
Speaker: S.R.D. Johnston (United Kingdom)
- **Modulation of Resistance to Hormonal Agents**
Speaker: to be announced

The Axilla – ‘A No Go Zone?’

Surgical treatment of the axilla is increasingly being questioned. Just how important is it to identify and remove all the identifiable cancer in the axilla, etc.

Chair: R. Jakesz (Austria)

Chair: E.J.T. Rutgers (The Netherlands)

- **No Axillary Surgery in Breast Cancer?**
Speaker: S. Alran (France)
- **The Sentinel Node Biopsy is Positive: No Axillary Clearance?**
Speaker: H.S. Cody (USA)
- **The Management of the Axilla Around Neo-Adjuvant Chemotherapy**
Speaker: G. van Tienhoven (The Netherlands)

Why Does Age Matter?

How do clinicians take the age of the patient into account when deciding on treatments: what are the particular challenges for younger and older women?

Chair: S. Erdem (Turkey)

Chair: H. Wildiers (Belgium)

- **Breast Cancer in the Young**
Speaker: S. Loibl (Germany)
- **Breast Cancer in the Elderly**
Speaker: L. Biganzoli (Italy)
- **Local Treatment**
Speaker: I. Kunkler (United Kingdom)

EUROPA DONNA Session 16.00-17.30

Survivorship

Chair: G. Abela (Malta)

- **Cancer Survivorship: NCI Research and Insights into this New and Growing Area**
Speaker: J. Rowland (USA)
- **A Young Survivor's Perspective**
Speaker: M. Miklavcic (Slovenia)
- **A Twenty Year Survivor's Perspective**
Speaker: I. Kössler (Sweden)

EUROPA DONNA 'Wrap up' Session 17.30 - 18.30

Chair: N. Zernik (France)

Speakers: to be announced

Challenge the Expert 17.30 - 18.30

Managing HER2 Overexpression in Breast Cancer

Moderator: R. Greil (Austria)

Expert: M. Piccart (Belgium)

Expert: M. Untch (Germany)

Expert: C. Denkert (Germany)

Expert: N.S. Russell (The Netherlands)

THURSDAY 22 MARCH 2012

Teaching Lectures

08.00 - 08.45

Clinical Management of Triple Negative Breast Cancer

Chair: M. Colleoni (Italy)

Speaker: A. Tutt (United Kingdom)

Clinical Applications of Circulating Tumour Cells

Chair: D.F. Hayes (USA)

Speaker: B. Rack (Germany)

Oncoplastic Surgery

Chair: M. Dixon (United Kingdom)

Speaker: I.T. Rubio (Spain)

Issues Around Hereditary Breast Cancer and Local Treatment

Chair: Y. Kirova (France)

Speaker: H.S.A. Oldenburg (The Netherlands)

Tumour Microenvironment

Chair: L.J. van 't Veer (USA)

Speaker: Z. Werb (USA)

**EUROPA DONNA
Teaching Lecture**

08.00 - 08.45

Managing/Monitoring Adverse Effects of Treatments

Chair: A. Bonifacino (Italy)

Fertility

Speaker: S. Loibl (Germany)

Menopausal Symptoms, Osteoporosis

Speaker: M.L. Brandi (Italy)



International Breast
Ultrasound School

**Where Do We Stand in
Advanced Breast Ultrasound?**

08:30 - 12:45

A workshop presented by the International Breast Ultrasound School (IBUS) in partnership with the 8th European Breast Cancer Conference

Workshop Conveners

A. Munding (DK)

R. Wilson (UK)

IBUS is dedicated to promoting best practice in breast ultrasound around the world. Recent advances in technology mean that ultrasound is now an essential part of the diagnosis and assessment of breast disease. This technique can provide invaluable information not only about the presence of disease but about its size, extent and nature. It is the technique of choice for guiding breast biopsy in many lesions and can be used successfully to assess the presence of associated axillary disease. In the future, ultrasound is likely to play an important role in the targeting of chemotherapeutic agents in the breast. This workshop will provide an overview of current state-of-art in breast ultrasound and introduce future developments.

Programme

- **Welcome**
Chair: A. Munding (Germany)
- **Review and New Perspectives of Advanced Ultrasound Technology**
Speaker: C. Weismann (Austria)
- **New Understanding of Breast Anatomy Using High Resolution Ultrasound**
Speaker: G. Rizzatto (Italy)
- **What Has Changed in BI-RADS for Ultrasound - Update**
Speaker: E.B. Mendelson (USA)
- **Where Do We Stand in Breast Interventions - Update**
Speaker: R. Wilson (United Kingdom)
- **Coffee Break**
- **Ultrasound of Breast and Axilla - Live Demonstration**
Speaker: H. Madjar (Germany)
- **Technique of Minimal Invasive Puncture - Live Demonstration**
Speaker: C. Weismann (Austria)
- **Vacuum Assisted Biopsy Tools - Live Demonstration**
Speaker: A. Munding (Germany)
- **Where Do We Stand in Axillary Staging - Update**
Speaker: A. Munding (Germany)
- **Intraoperative Imaging - The New Evolving Concept**
Speaker: E. Durante (Italy)
- **Actual and Future Role of Ultrasound - Update**
Speaker: H. Madjar (Germany)
- **Discussion and Closing**
Speaker: R. Wilson (United Kingdom)

Patient Management Workshops 09.00 - 10.00

Clinical Management of Triple Negative Breast Cancer

Coordinator: M. Colleoni (Italy)

Coordinator: A. Tutt (United Kingdom)

Oncoplastic Surgery

Coordinator: M. Dixon (United Kingdom)

Coordinator: I.T. Rubio (Spain)

Issues Around Hereditary Breast Cancer and Local Treatment

Coordinator: Y. Kirova (France)

Coordinator: H.S.A. Oldenburg (The Netherlands)

Challenge the Expert 09.00 - 10.00

Anthracyclines in Breast Cancer

Moderator: S. Verma (Canada)

Expert: J. Bartlett (United Kingdom)

Expert: A. Di Leo (Italy)

Expert: J. Crown (Ireland)

Expert: T. Suter (Switzerland)

Debates 11.45 - 12.45

This House Believes That Bisphosphonates Should be Part of the Routine Treatment of Early Breast Cancer

Moderator: C. Jackisch (Germany)

Speaker in favour: M. Gnant (Austria)

Seconder: R.E. Coleman (United Kingdom)

Speaker against: R. Bell (Australia)

Seconder: L.A. Costa (Portugal)

This House Believes That Size Matters in Margins

Moderator: M. van de Vijver (The Netherlands)
Speaker in favour: M. Kaufmann (Germany)
Seconder: B. Chua (Australia)
Speaker against: M. Dixon (United Kingdom)
Seconder: A. Fourquet (France)

Keynote Symposium 14.00 - 15.30

The Biology of Metastasis in Breast Cancer

Chair: C.C. Zielinski (Austria)
Chair: N. Harbeck (Germany)

- **Mouse Models of Metastatic Breast Cancer**
Speaker: J. Jonkers (The Netherlands)
- **Targeting and imaging invasion and metastasis**
Speaker: M. Frame (United Kingdom)
- **A Clinician's Perspective on Metastatic Breast Cancer: Many diseases - We Need to Understand the Biology**
Speaker: D.F. Hayes (USA)

Clinical Science Symposia 16.00 - 17.30

When to Add Chemotherapy to Endocrine Therapy and Endocrine Sensitivity

It is increasingly clear that there are patients who benefit little from adjuvant chemotherapy when given over and above standard endocrine therapy. Numerous attempts have been to identify these groups – and molecular biology offers more options every year, but full validation of the best way to implement this in the clinic remains elusive

Chair: P. Dubsky (Austria)
Chair: M. Gnant (Austria)

- **How Much Genetic Sequencing Can Help?**
Speaker: C. Sotiriou (Belgium)
- **Added Value Tools**
Speaker: A. Borg (Sweden)
- **What I Need to Know in the Clinic**
Speaker: H. Bonnefoi (France)

Controversies on Breast Cancer Treatment / Breast Conservation

Breast conservation is a standard of care...yet there remain many questions about for which patients this is an appropriate treatment, and the most appropriate radiotherapy treatments after breast conservation.

Chair: A. Fourquet (France)
Chair: M. Dixon (United Kingdom)

- **Imaging in Breast Conservation**
Speaker: S. Heywang - Köbrunner (Germany)
- **Radiotherapy in Breast Conservation**
Speaker: J. Yarnold (United Kingdom)
- **Breast Conservation in Controversial Cases - Surgical Techniques**
Speaker: K. Clough (France)

The Management of Pre-Invasive Breast Cancer

The aim of this session is to update the audience on the current thinking around the biology, diagnosis and management of non-invasive cancer. Controversies/challenges for future research will include those around management at different ages, management of lesions that increase the risk of developing malignancy, and the necessity of 'clear margins'.

Chair: M. van de Vijver (The Netherlands)
Chair: N. Bundred (United Kingdom)

- **Magnetic Resonance Imaging of High-Risk Lesions and DCIS**
Speaker: F. Sardanelli (Italy)
- **Surgery in Relation to Biology**
Speaker: N. Bundred (United Kingdom)
- **Radiotherapy in Relation to Biology**
Speaker: B. Chua (Australia)
- **The Pathology of DCIS: Take it or Leave it**
Speaker: J. Wesseling (The Netherlands)

Barriers to Effective Care

The aim of this study is to understand barriers that exist for patients getting the best care for their breast cancer, irrespective of what treatments are reimbursed /available. The barriers to be discussed include those at national level, such as specialisation of specialists, regional level perhaps due to inequities in access due to geography, or due to interactions/issues within the treatment centre/hospital. We will also discuss why the growing difficulties we face in doing clinical research are a further barrier to patients getting the best care.

Chair: E.J.T. Rutgers (The Netherlands)

Chair: B. Borisch (Switzerland)

- **External Barriers to Effective Care in Clinical Research**
Speaker: M. Piccart (Belgium)
- **Advocacy Perspective on Barriers to Effective Care**
Speaker: B. Borisch (Switzerland)
- **Internal Barriers to Effective Care (Staff Dynamics)**
Speaker: L. Fallowfield (United Kingdom)
- **Political Barriers to Effective Care**
Speaker: V. Mazeau Woynar (France)

EUROPA DONNA session 16.00 - 17.30

Advocating for Metastatic Breast Cancer Patients

Chair: S. Knox (Italy)

- **Patient perspective on issues and Needs**
Speaker: D. Fenech (Malta)
- **Patient perspective on issues and Needs**
Speaker: to be announced
- **The Breast Cancer Care Initiative UK**
Speaker: E. Reed (United Kingdom)
- **The Role of Breast Cancer Nurses and the Special Breast Unit**
Speaker: Y. Wengström (Sweden)

Panel Discussion

What Should the 5th Edition of the EU Guidelines Contain Regarding Metastatic Breast Cancer?

EUROPA DONNA 17.30 - 18.30 'Wrap up' Session

Chair: A. Scharpantgen (Luxembourg)

Speakers: to be announced

Challenge the Expert 17.30 - 18.30

Diagnosis in Breast Cancer

Moderator: T. Cufer (Slovenia)

Expert: A. Tardivon (France)

Expert: M. van de Vijver (The Netherlands)

Expert: T. Helbich (Austria)

Expert: C. Markopoulos (Greece)

FRIDAY 23 MARCH 2012

Teaching Lectures 08.00 - 08.45

Managing the Toxicity of Aromatase Inhibitors

Chair: R.E. Coleman (United Kingdom)

Speaker: P. Neven (Belgium)

Hypofractionation

Chair: P. Poortmans (The Netherlands)

Speaker: J. Yarnold (United Kingdom)

Advances in Breast Cancer Imaging

Chair: U. Bick (Germany)

Speaker: R. Wilson (United Kingdom)

Supporting Breast Cancer Patients in Different Cultures

Chair: E. Verschuur-van der Voort (The Netherlands)

EUROPA DONNA Houses

Speaker: S. Kyriakides (Cyprus)

■ **Maggie Centres**

Speaker: L. Lee (United Kingdom)

■ **Non-Coding RNA's**

Chair: Z. Werb (USA)

Speaker: L. Santarpia (Italy)

**EUROPA DONNA
Teaching Lecture**

08.00 - 08.45

Lifestyle Factors and Breast Cancer - Recent Study Results and What They Mean

Chair: S. Knox (Italy) – Update on Breast Health Day Campaigns

Speaker: I. Romieu (France)

**Patient Management
Workshops**

09.00 - 10.00

Managing the Toxicity of Aromatase Inhibitors

Coordinator: R.E. Coleman (United Kingdom)

Coordinator: P. Neven (Belgium)

Coordinator: W. Bolten (Germany)

Advances in Breast Cancer Imaging

Coordinator: U. Bick (Germany)

Coordinator: R. Wilson (United Kingdom)

Challenge the Expert

09.00 - 10.00

Genomic Profiling in Breast Cancer

Moderator: D.F. Hayes (USA)

Expert: L.J. van 't Veer (USA)

Expert: C.M. Perou (USA)

Expert: C. Sotiriou (Belgium)

Expert: T. Sørli (Norway)

Debates**11.45 - 12.45**

This House believes That Breast Cancer Oncologists Must Prescribe Lifestyle Changes More Than Drugs*Moderator:* B. Borisch (Switzerland)*Speaker in favour:* A. Howell (United Kingdom)*Seconder:* W. Janni (Germany)*Speaker against:* J. Crown (Ireland)*Seconder:* K. Pritchard (Canada)**This House Believes That Metastatic Disease Should be Biopsied***Moderator:* G. Viale (Italy)*Speaker in favour:* J. Bergh (Sweden)*Seconder:* A. Vincent-Salomon (France)*Speaker against:* to be announced*Seconder:* T. Decker (Germany)

Keynote Symposium**14.00 - 16.00**

Key Messages to Take Back to Your Practice on Monday Morning*Chair:* D.A. Cameron (United Kingdom)*Chair:* E. Bergsten-Nordstrom (Sweden)■ **Key Messages From The Advocacy Perspective***Speaker:* E. Bergsten-Nordstrom (Sweden)■ **Key Messages From the Conference***Speaker:* D.A. Cameron (United Kingdom)■ **How Lifestyle Interacts With Genes to Alter the Risk of Breast Cancer***Speaker:* V. Beral (United Kingdom)■ **Breast Cancer Implications for Future Generations***Speaker:* to be announced

SATURDAY 24 MARCH 2012

Lay Public Programme**09.00 - 12.00**

The lay public programme provides an innovative opportunity to raise the profile of breast cancer and patient advocacy in Austria and Europe by enabling dialogue between specialists involved in the diagnosis, treatment and management of breast cancer, and the concerned public.

Also, internationally renowned and effective patient advocates will be present. Patients, relatives, and health care providers alike will give meaning to their experiences relating to 'access to clinical trials' and discuss the obstacles and opportunities this entails, to ultimately develop a better mutual understanding of breast cancer treatment and care in Europe.

Programme to be announced - please check our website www.ecco-org.eu

ABSTRACT SUBMISSION DEADLINE: 15 NOVEMBER 2011

Abstracts can only be submitted online via the ECCO website at: www.ecco-org.eu. Abstracts submitted by regular mail, fax or e-mail will NOT be accepted.
ABSTRACT SUBMISSION DEADLINE: 15 NOVEMBER 2011, 09:00 p.m. CENTRAL EUROPEAN TIME

The EBCC-8 abstract submission programme is available on the ECCO website at: www.ecco-org.eu. Please follow the instructions on the screen. For questions regarding the on-line submission process, e-mail: pat.vanhove@ecco-org.eu.

It is strongly advised that presenting authors should submit their abstract before the day of the deadline, otherwise authors may experience technical delay due to server overload.

The selection of abstracts for oral and poster presentations will be made by the Scientific Committee in January 2012. The presenting author will receive an e-mail with the result of the review and the Scientific Committee's decision on the abstract by early February 2012.

The 8th European Breast Cancer Committee strongly encourages the submission of Late Breaking Abstracts relating to important data that were not fully available by the general abstract submission deadline.

Late-breaking abstracts might include the results of a practice-changing prospective Phase III clinical trial, a Phase II study showing anti-tumour activity in a novel context, an early clinical trial with novel proof-of-principle data, the demonstration of novel cancer biology with therapeutic implications.

Abstracts on case studies will be rejected.

ABSTRACT POLICIES AND REGULATIONS

WITH THE SUBMISSION OF AN ABSTRACT TO EBCC-8 THE FIRST (PRESENTING) AUTHOR:

- Certifies to be an investigator with a substantial involvement in the clinical study presented in the abstract.
- Accepts responsibility for the accuracy of the submitted abstract (please proofread the abstract carefully prior to submission!).
- Accepts the rule that a first (presenting) author can be the first (presenting) author of only one abstract.
- Accepts to be the contact person for all correspondence about the abstract and inform co-authors about its status.
- Confirms that all co-authors are aware of and agree to the content of the abstract and support the data presented.
- If the data and conclusions submitted in the abstract have been presented prior to the EBCC-8 congress, the Scientific Committee reserves the right to deselect the abstract.
- Certifies that the information in the abstract is for exclusive presentation in the EBCC-8 Scientific Programme and will not be presented as such during the Conference at any industry-related Satellite Symposia.
- States that for studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and properly informed consent given where appropriate.
- Agrees that abstracts submitted to EBCC-8 are considered both confidential and embargoed from the time of submission. Abstracts presented at EBCC-8 are embargoed until the first day of the Conference.
- Identifies any financial interest in products or processes described in the abstract. The presenting author is requested to tick the 'Conflict of interest' box when submitting the abstract and to provide disclosure of interests and relationships through the abstract submission programme. This includes stock ownership, membership on an advisory board or board of directors, corporate-sponsored research, or other substantive relationships for the products/ technologies being discussed, AND any that compete with those being discussed.
- Releases the copyright to ECCO and gives permission for the abstract, when selected for presentation, to be published in the EBCC Abstract book with the EJC Supplement (electronic format), as well as on the ECCO website.
- If the data and conclusions submitted in the abstract have been presented prior to the EBCC-8 Conference, the Scientific Committee reserves the right to deselect the abstract.

ABSTRACT PREPARATION AND SUBMISSION

ABSTRACT FORMAT

- The **title of the abstract** should be brief and objectively describe the study. Do not use capital letters in the title except for words that are always capitalised and do not use non-standard abbreviations. Commercial names may not be used in the abstract title (generic names only).
- **No more than 10 authors** can be listed with institutional affiliations, cities and countries only. Mailing addresses and academic degrees should not be mentioned in the author's list. For cooperative study groups, you may give the name of the group instead of individual institutional affiliations or include the name of the group in the title of the abstract.
- Abstracts should be structured in such a way as to include the following 4 sections:
 1. Background: an introductory sentence indicating the purpose of the study
 2. Material and methods: a brief description of pertinent experimental procedures
 3. Results: a summary of the results of the research
 4. Conclusions: a statement of the main conclusions
- The on-line abstract submission procedure will not accept abstracts that exceed **2,500 characters** (body of the abstract, including spaces and table).
- **Only one data table** is permitted in the body of the abstract. Illustration and figures are not allowed and will be deleted if submitted.
- **Abbreviations** may be used if standard or if spelled out and defined at the first use (put in parentheses immediately after the first mention of a term or phrase). Compounds should be mentioned with the generic name, in lower cases. Commercial names are admitted in the text, with an[®], and if in brackets following the generic name, i.e. 'generic (Commercial[®])'.
- The abstract must be submitted in **good English**. The Scientific Committee reserves the right to reject those abstracts which are presented in poor English, or may request an immediate revision by the presenter.
- **Presentation preference** - oral, poster or no preference: the final decision on the presentation format will be made by the Scientific Committee.

ABSTRACT SUBMISSION PROCEDURE

Abstracts must be submitted online, through the ECCO website at: www.ecco-org.eu.

Essential information:

- When finished with the online submission, click the 'FINAL SUBMISSION' button for the final submission of your abstract. As a confirmation of your submission, a message will appear on the screen informing you the abstract has been successfully submitted to our database.
- If you need to edit your abstract at a later stage please click 'SAVE AND CLOSE'. This button allows you to update your abstract before final submission.
- Within 48 hours of submission, the presenting author will receive an e-mail to confirm that ECCO has received the abstract. This confirmation of abstract does not mean your abstract has been selected for presentation.
- In case the confirmation from the EBCC-8 Secretariat is not received, please contact the Secretariat via e-mail at: pat.vanhove@ecco-org.eu, within one week after the submission of the abstract.
- Submitting an abstract for presentation at EBCC-8 does not constitute registration for the Conference. Abstract presenters must register to attend EBCC-8 by following the instructions for registration on the website.

PLEASE NOTE: after clicking 'SAVE AND CLOSE', your abstract is NOT submitted. You need to return to the abstract submission page, finalise your abstract and click 'FINAL SUBMISSION'. No changes can be made after Final Submission

ABSTRACT SELECTION PROCESS

Abstracts submitted for presentation at EBCC-8 will be reviewed by an international panel of experts in the field of the subject and will be judged solely on the data submitted.

The following presentation formats are applicable at EBCC-8:

Oral presentation: Abstract/Late Breaking Abstracts will be selected for oral presentation to be included in the Clinical Science Symposia and Keynote symposium.

Poster session: abstracts that have been selected for presentation in poster format. The posters are grouped by topic and are displayed for one day. A specific time is devoted to poster viewing.

Poster discussion: A number of poster abstracts will be selected by the Scientific Committee for poster discussion.

Withdrawal of abstracts: Abstracts submitted for presentation in EBCC-8 can be withdrawn until 18 November 2011. After this date, abstracts selected for oral or poster presentation should be presented. If the presenting author of a selected abstract cannot attend, (s)he should assign a replacement and inform the EBCC-8 secretariat of the replacement as soon as possible.

ABSTRACT CATEGORIES

Please select only one topic that refers to the main subject of the abstract.
The Scientific Committee has the authority to re-categorise the abstract.

- Adjuvant and Neo-Adjuvant Therapy
- Advocacy and Education
- Detection, Diagnosis and Imaging
- Ductal and Lobular Carcinoma in Situ
- Epidemiology, Prevention, Screening
- Locally Advanced and Metastatic Disease
- Nursing
- Pathology
- Pharmacology, New Drug Development
- Predictive and Prognostic Factors
- Radiotherapy
- Side Effects of Treatment, Follow-up, Management and Care, Psychosocial Aspects
- Surgical Management (Including Reconstructive Surgery and Sentinel Node)
- Targeted Treatment
- Molecular Biology, Tumour Biology and Immunology
- Breast Cancer in Young and Elderly
- Miscellaneous (*only if none of the above topics apply to the abstract subject*)

LATE BREAKING ABSTRACTS

**LATE BREAKING ABSTRACT SUBMISSION DEADLINE IS 15 FEBRUARY 2012,
9 PM CENTRAL EUROPEAN TIME.**

DEFINITION

- Late-breaking abstracts should highlight novel and practice changing studies.
The late-breaking abstract deadline is not intended to be merely an extension of the general submission deadline.
It will focus on capturing abstracts with ground-breaking and unique data that would not otherwise have been presented at the Conference.
- Examples of suitable late-breaking abstracts might include the results of a practice-changing prospective Phase III clinical trial, a Phase II study showing anti-tumour activity in a novel context, an early clinical trial with novel proof-of-principle data, the demonstration of novel cancer biology with therapeutic implications; in each case the results should not have been fully available by the general abstract submission deadline.
- If the data and conclusions submitted in the abstract have been presented prior to the EBCC-8 Conference, the Scientific Committee reserves the right to deselect the abstract.

POLICY

- Abstracts from translational, Phase I, Phase II or Phase III studies for which preliminary data were not available at the time of the abstract submission deadline of 15 November 2011, will be considered for presentation at the 8th European Breast Cancer Conference.
- Data from the long-term follow-up of previously presented clinical trials may be submitted only if significant new information can be shown. In this case, please ask for special consideration by e-mail.
- Interim analysis of a prospective randomised clinical trial will be considered only if it is performed as planned in the original protocol and is statistically valid. If your abstract involves interim analysis, explain the details of your study in the body of the abstract.
- Late-breaking abstracts will be considered for oral presentation in proffered papers sessions or in one of the Keynote Symposia. If a late-breaking abstract does not meet the criteria for oral presentation in one of these two sessions, the abstract will be rejected.
- Late-breaking abstracts will undergo formal peer-review evaluation by the Scientific Committee.

SUBMISSION

Online submission will be open
from 1 February 2012

The first (presenting) author must:

- Submit a late breaking abstract by the submission deadline of 15 February 2012
- Complete the section on the reasons why this abstract should be considered as late-breaking (In order for the abstract to be considered late breaking, this section must be completed).
- Ensure that submission of the abstract follows the general abstract submission guidelines and regulations and the specific guidelines listed above

- Ensure abstracts that include clinical trial data include the following information in the body of the abstract: Trial abbreviation, Trial Registry Number or ID background, Objective, Design, Population Studied (including sample size), Intervention, Outcome Measure(s), Analysis, Trial Status, Trial Sponsor(s).

- Ensure that abstracts contain final results and incorporate statistical analysis. Abstracts submitted stating 'results to follow' or similar deferment will not be considered.

SELECTION

Abstracts will be judged solely on the data submitted. The first (presenting) author will receive confirmation of acceptance or rejection before the end of February 2012.



EMBARGO POLICY FOR LATE BREAKING, ORAL PRESENTATIONS AND ABSTRACTS SELECTED FOR MEDIA

- Abstracts submitted to the 8th European Cancer Conference are considered to be embargoed until the first day of the scientific programme.
- Information contained in the abstract as well as additional data and information to be presented must not be made public before the abstract has been published or presented at the 8th European Cancer Conference.
- The first author and co-authors must not release the research/study to news media.
- If the policy is violated, the abstract will be automatically withdrawn from presentation and from publication online.

FELLOWSHIPS FOR INDIVIDUALS FROM COUNTRIES WITH LIMITED RESOURCES

The Organising Committee will award a number of Fellowship Grants to young doctors, basic scientists, nurses and others involved in breast cancer care and advocacy, from countries with limited resources to attend the 8th European Breast Cancer Conference in Vienna.

To be considered for a Fellowship Grant the applicant should:

- Submit an abstract to EBCC-8. Applicants whose abstracts have been accepted for oral or poster presentation at EBCC-8 in Vienna will be considered first.
- Be under the age of 40.
- Provide a letter from the Head of the Department/Organisation stating that the applicant is not the recipient of any other financial support.
- Provide a two page CV (including date of birth).

Each Fellowship Grant shall be worth a free registration, free accommodation for a maximum of 4 nights and reimbursement of travel costs up to a maximum of 500 EUR (reimbursement after the Conference)

**The deadline for receipt of applications:
15 November 2011**

Please send your application to Pat Vanhove by email pat.vanhove@ecco-org.eu
Kindly mention in the subject title of your email the fellowship you are applying for

The Executive Committee will select the recipients of the Fellowship Grant. Successful applicants will be notified early February 2012.

FELLOWSHIPS FOR INDIVIDUALS FROM DEVELOPING COUNTRIES

The Organising Committee will award a number Fellowship Grants to young doctors, basic scientists, nurses and others involved in breast cancer care and advocacy, from developing countries to attend the European Breast Cancer Conference in Vienna.

To be considered for a fellowship grant the applicant should:

- Submit a one page description of a project that optimises breast cancer care in developing countries.
- Provide a letter from the Head of the Department/Organisation stating that the applicant is not the recipient of any other financial support.
- Provide a two page CV.

The deadline for receipt of applications: 15 November 2011

Please send your application to Pat Vanhove by email pat.vanhove@ecco-org.eu
Kindly mention in the subject title of your email the fellowship you are applying for

Each Fellowship Grant shall be worth a free Conference registration, free accommodation for a maximum of 4 nights and reimbursement of travel costs up to a maximum of 1000 EUR (reimbursement after the Conference).

The Executive Committee will decide select the recipients of the Fellowship Grants. Successful applicants will be notified early February 2012.

EUROPA DONNA FELLOWSHIP GRANTS

The Organising Committee will award five EUROPA DONNA fellowships to breast cancer advocates.

To be considered for a EUROPA DONNA Fellowship the following criteria should apply:

- Breast cancer survivor
- Under the age of 40 years
- Fluent in English
- Demonstrated some involvement in breast cancer advocacy work for at least one year

To apply:

The individual must provide a short abstract (400 words) about current advocacy activities and indicate why EBCC-8 will be important to your future advocacy work. This paper should be submitted to the Head Office of EUROPA DONNA for the Board to review.

Each fellowship grant shall be worth a free Conference registration, free accommodation for a maximum of 4 nights and reimbursement of travel costs up to a maximum of 500 EUR (reimbursement after the Conference).

Applicants who meet the above criteria should send their abstracts to EUROPA DONNA:

EUROPA DONNA - The European Breast Cancer Coalition
Piazza Amendola 3
20149 Milan, Italy
Tel: +39 02 3659 2280
e-mail: info@europadonna.org

Deadline for receipt of applications is 16 September 2011.

The applications will be reviewed by the EUROPA DONNA Board and EBCC-8 Executive Scientific Committee. Successful applicants will be notified in early February 2012.

THE EUROPEAN BREAST CANCER ARTS AND HUMANITIES AWARD

Call for Nominations

The Organising Committee of the 8th European Breast Cancer Conference invites nominations for the EBCC Arts and Humanities Award, a prize that recognises an outstanding contribution to the arts/humanities and which has a direct relationship to the fight against breast cancer.

The EBCC Arts and Humanities Award will be awarded to the individual who has 'made a difference' through an artistic or humanistic activity such as: artwork, dance, film, literature, music, photography or poetry and whose contribution and personal achievements reflect the efforts and vision of the EBCCs.

It is important that such efforts do not go unrecognised, thus we invite you to look within your respective countries and nominate an individual whom you believe deserves this significant recognition on the occasion of the 8th European Breast Cancer Conference in Vienna.

The European Breast Cancer Arts and Humanities Award is worth 1.500 EUR including an all expenses paid trip to attend EBCC-8.

Please submit your nomination directly to:

EUROPA DONNA - the European Breast Cancer Coalition
Piazza Amendola 3
20149 Milan, Italy
Tel: +39 2 3659 22 80
e-mail: info@europadonna.org

Nominations must be received by 1 December 2011.

Registration is now open online – please visit: www.ecco-org.eu.

(select 'Congresses and conferences' > 'EBCC 8').

Participants are encouraged to register early in order to benefit from significant savings on fees:

'Deadline' applies to both receipt of registration and payment	Early Rate Deadline: 24 October 2011	Regular Rate Deadline: 13 February 2012	Late Rate Deadline: 20 March 2012
Members (*)	350 EUR	650 EUR	875 EUR
Non-Members	555 EUR	780 EUR	875 EUR
Students/Junior Participants 'in training' (**)	200 EUR	300 EUR	300 EUR
Optional Social Event (***)	tickets 55 EUR	tickets 55 EUR	tickets 55 EUR

All registration fees include local VAT (20%)

* Discounted membership rates apply to individuals who are a member of one of the following professional associations: EORTC, EUROPA DONNA, EUSOMA.

** Confirmation of 'in training' status and a letter from the Head of Department is required. These documents have to be sent to the EBCC-8 Secretariat by Fax: +32 (0)2 775 02 00.

*** This ticket gives access to the social event (networking reception and musical/cultural event) held on Thursday 22 March 2012.

For information regarding group registration, accommodation and travel through the EBCC-8 officially appointed local housing agent and airline network please visit: www.ecco-org.eu (select 'Congresses and conferences' > 'EBCC 8').





www.ecco-org.eu

EBCC
European
Breast Cancer
Conference
8

8TH EUROPEAN BREAST CANCER CONFERENCE

21-24 March 2012

VIENNA - AUSTRIA



Registration Form

TITLE & CONTACT DETAILS

☐ Prof. ☐ Dr. ☐ Mr. ☐ Mrs. ☐ Ms.

Last Name:

First Name:

Institute/Company: Department:

Address:

City: Postal Code: Country:

International Tel. Number:

e-mail:

BILLING ADDRESS

Institute/Company:

Address:

City: Postal Code: Country:

VAT Number:

International Tel. Number:

e-mail:

SPECIALISATION IN MAIN TUMOUR TYPES (please select all that apply)

- | | | |
|--|--|--|
| <input type="checkbox"/> Breast | <input type="checkbox"/> Kidney | <input type="checkbox"/> Prostate |
| <input type="checkbox"/> Bladder | <input type="checkbox"/> Liver | <input type="checkbox"/> Soft Tissue Sarcoma |
| <input type="checkbox"/> Blood | <input type="checkbox"/> Lung | <input type="checkbox"/> Stomach |
| <input type="checkbox"/> Bone | <input type="checkbox"/> Melanoma and Skin | <input type="checkbox"/> Thyroid |
| <input type="checkbox"/> Brain | <input type="checkbox"/> Neuroendocrine | <input type="checkbox"/> Other |
| <input type="checkbox"/> Colorectal | <input type="checkbox"/> Ocular | <input type="checkbox"/> All |
| <input type="checkbox"/> Cervix | <input type="checkbox"/> Ovarian | |
| <input type="checkbox"/> Head and Neck | <input type="checkbox"/> Pancreatic | |

FIELD OF INTEREST (please select all that apply)

- | | | |
|---|--|---|
| <input type="checkbox"/> Advocacy | <input type="checkbox"/> Nursing | <input type="checkbox"/> Policy |
| <input type="checkbox"/> Basic Science | <input type="checkbox"/> Paediatrics | <input type="checkbox"/> Radiotherapy |
| <input type="checkbox"/> Clinical Research | <input type="checkbox"/> Palliative Care | <input type="checkbox"/> Systemic Therapy |
| <input type="checkbox"/> Drug Development | <input type="checkbox"/> Pathology | <input type="checkbox"/> Surgery |
| <input type="checkbox"/> Early Drug Development | <input type="checkbox"/> Pharmacy | <input type="checkbox"/> Translational Research |
| <input type="checkbox"/> Geriatric Oncology | <input type="checkbox"/> Psychosocial Oncology | <input type="checkbox"/> Other |

PROFESSION

- | | | |
|---|--|---|
| <input type="checkbox"/> Basic Scientist | <input type="checkbox"/> Gynaecologist | <input type="checkbox"/> Neurologist |
| <input type="checkbox"/> Clinical Trial Coordinator | <input type="checkbox"/> Haematologist | <input type="checkbox"/> Neuro-Oncologist |
| <input type="checkbox"/> General Physician | <input type="checkbox"/> Medical Affairs | <input type="checkbox"/> Neuro-Surgeon |
| <input type="checkbox"/> General Surgeon | <input type="checkbox"/> Medical Oncologist | <input type="checkbox"/> Nurse |
| <input type="checkbox"/> Oncology Pharmacist | <input type="checkbox"/> Radiotherapist | <input type="checkbox"/> Urologist |
| <input type="checkbox"/> Paediatric Oncologist | <input type="checkbox"/> Statistician | <input type="checkbox"/> Other |
| <input type="checkbox"/> Patient Advocate | <input type="checkbox"/> Student | |
| <input type="checkbox"/> Pathologist | <input type="checkbox"/> Surgical Oncologist | |
| <input type="checkbox"/> Radiologist | <input type="checkbox"/> Translational Scientist | |

PROFESSIONAL MEMBERSHIP(S)

- | | | |
|--------------------------------|---------------------------------------|--|
| <input type="checkbox"/> BIG | <input type="checkbox"/> ESGO | <input type="checkbox"/> EUSOMA |
| <input type="checkbox"/> EACR | <input type="checkbox"/> ESMO | <input type="checkbox"/> Flims Alumni Club |
| <input type="checkbox"/> EANM | <input type="checkbox"/> ESO | <input type="checkbox"/> Myeloma Euronet |
| <input type="checkbox"/> EANO | <input type="checkbox"/> ESOP | <input type="checkbox"/> OECI |
| <input type="checkbox"/> EAU | <input type="checkbox"/> ESSO | <input type="checkbox"/> SIOP(Europe) |
| <input type="checkbox"/> EBMT | <input type="checkbox"/> ESTRO | <input type="checkbox"/> UICC |
| <input type="checkbox"/> ECL | <input type="checkbox"/> EUROPA DONNA | <input type="checkbox"/> None of the above |
| <input type="checkbox"/> EONS | <input type="checkbox"/> EUROPA UOMO | |
| <input type="checkbox"/> EORTC | <input type="checkbox"/> EUROSkin | |

REGISTRATION FEES (please tick as appropriate)

'Deadline' applies to both receipt of registration and payment	Early Rate Deadline: 24 October 2011	Regular Rate Deadline: 13 February 2012	Late Rate Deadline: 20 March 2012
Members (*)	<input type="checkbox"/> 350 EUR	<input type="checkbox"/> 650 EUR	<input type="checkbox"/> 875 EUR
Non-Members	<input type="checkbox"/> 555 EUR	<input type="checkbox"/> 780 EUR	<input type="checkbox"/> 875 EUR
Students/Junior Participants 'in training' (**)	<input type="checkbox"/> 200 EUR	<input type="checkbox"/> 300 EUR	<input type="checkbox"/> 300 EUR
Optional Social Event (***)	<input type="checkbox"/> tickets 55 EUR	<input type="checkbox"/> tickets 55 EUR	<input type="checkbox"/> tickets 55 EUR

All registration fees include local VAT (20%)

* Discounted membership rates apply to individuals who are a member of one of the following professional associations: EORTC, EUROPA DONNA, EUSOMA.

** Confirmation of 'in training' status and a letter from the Head of Department is required. These documents have to be sent to the EBCC-8 Secretariat by Fax: +32 (0)2 775 02 00.

*** This ticket gives access to the social event (networking reception and musical/cultural event) held on Thursday 22 March 2012.

Payment Method

- ☐ Paid by credit card (preferred):
- ☐ Eurocard/Mastercard ☐ Visa ☐ American Express

Card Number:..... Expiry Date:.....

Owner's name as show on the card:.....

Control/CVC-Code:.....

- ☐ Remitted by bank transfer to the EBCC-8 Registration Account :

Account number: 733-0418257-23

IBAN: BE92 7330 4182 5723, BIC/SWIFT Code: KREDBEBB

KBC Bank, Chaussée de Wavre 1662, B-1160 Brussels, Belgium

Please clearly indicate the name of the participant and 'EBCC-8' in all your remittances.

Replacements and Cancellations

Replacements (= delegate name change) of confirmed registrations are possible at a charge of 50 EUR.

Cancellations of confirmed registrations are subject to a charge of 100 EUR per participant provided the cancellation is received before 13 February 2012. For cancellations received after this date no refunds will be made.

By completing this form I accept the terms and conditions of registration mentioned above.

If posting or faxing please sign and date below.

Date: Signature:

CATERING

Coffee breaks and lunches courtesy of the organisers will be scheduled during the Conference.

OFFICIAL CARRIER



STAR ALLIANCE

Save up to 20% on travel with the Star Alliance network

The Star Alliance™ member airlines are pleased to be appointed as the Official Airline Network for the 8th European Breast Cancer Conference. To obtain the Star Alliance Conventions Plus discounts, please quote the event code **SKo4A23** when calling the reservation office of a participating Star Alliance member airline.

For booking office information please visit: www.staralliance.com/conventionsplus.

Registered participants plus one accompanying person travelling to the event can be granted a discount of up to 20%, depending on the fare and class of travel. The participating airlines for this event will be announced: **www.ecco-org.eu**. Discounts are offered on most published business and economy class fares, excluding website/internet fares, senior and youth fares, group fares and Round the World fares.

Please note: For travel from Japan and New Zealand, special fares or discounts are offered by the participating airlines on their own network.

A valid passport is required for entry into Austria. A visa may be required for some countries. For information about visa and passports contact your local Austrian Embassy at least 3 months prior to your departure to join us in Vienna.

TRANSPORTATION

Participants registered for the entire duration of the European Breast Cancer Conference are entitled to one free public transport ticket.

SOCIAL EVENT

Thursday 22 March



Enlighten your focus - join us for an EBCC-8 celebration at the Belvedere

The Belvedere palaces with their extensive gardens are considered to be one of the world's finest Baroque landmarks. Built in the 18th century by the outstanding Baroque architect Johann Lucas von Hildebrandt (1668- 1745) Belvedere provides a spectacular view of Vienna.



The Upper Belvedere houses impressive collections of Austrian art including the world's largest Gustav Klimt collection (see front cover of this programme). Glittering highlights include Klimt's golden pictures *The Kiss* and *Judith I*, as well as great works by French Impressionists and Viennese Biedermeier paintings.

We invite you to join us for an evening buffet in a truly enchanting setting.

Price per person: 55 €

Tickets can be purchased via the Registration form or onsite in Vienna from the EBCC-8 Registration Desk.



ACCOMMODATION

Mondial Congress & Events has been appointed as the official local housing partner for EBCC-8 and is offering hotel accommodation and local services for both groups and individuals.

We kindly ask you to contact Mondial Congress & Events directly for any of these services; please do NOT contact the EBCC-8 Secretariat for such information.



Contact person - accommodation:
Monika Nikolaus
Mondial Congress & Events
Operngasse 20B, 1040 Vienna, Austria

Tel.: +43 (0)1 58804 0
Fax: +43 (0)1 58804 185
e-mail: ebcc8@mondial-congress.com

www.mondial-congress.com

Delegates are encouraged to book online via the ECCO website at: **www.ecco-org.eu** (select 'Congresses and conferences' > 'EBCC 8'). All rooms are booked on a first come first served basis. The deadline for hotel reservation is **17 February 2012**. After this date accommodation cannot be guaranteed by Mondial Congress & Events.

LOCAL SERVICES

As official Destination Management Company (DMC) during the EBCC8 Conference, Mondial Congress & Events will be responsible for planning, organising and coordinating the local services in Vienna, Austria.

With our vast experience in event management we are your reliable and creative partner – with your needs always at the forefront of our mind!

Finding the accommodation that will best meet your needs is just one way to make your EBCC experience as pleasant as possible.

Other services that Mondial Congress & Events can organise and manage for you include:

- Accommodation
- Transportation
- Meetings (outside the Congress Centre)
- Receptions (outside the Congress Centre)
- Dinners
- Other social events outside the hours of the official Conference Scientific Programme
- On-site staff
- Tours
- Room gifts
- Graphic design and printing

For further information, please contact:



Mondial Congress & Events
Operngasse 20B
1040 Vienna, Austria
ebcc8@mondial-congress.com
www.mondial-congress.com
Tel.: +43 1 58804 0
Fax: +43 1 58804 185

Hotel Registration Form

Mail or Fax before February 17, 2012 to:
Mondial Congress & Events
Operngasse 20b, 1040 Vienna, Austria
t +43 1 58804 - 0, f +43 1 58804 - 185
ebcc8@mondial-congress.com

*Please read the reservation conditions before completing this form.
Note that any reservation has to be guaranteed by the appropriate payment.
Use one form per delegate (photocopied registration forms allowed).*

A. PARTICIPANT INFORMATION

☐ Prof. ☐ Dr. ☐ Mr. ☐ Mrs. ☐ Ms.
Last Name: First Name:
Institute/Company: Department:
Address:
City: Postal Code: Country:
International Tel. Number:
e-mail*:

* Compulsory field as all confirmations are sent by e-mail!

B. HOTEL BOOKING

Hotel NAME Please choose a hotel from the list	Double Room Single Use	Double Room	Deposit
	<input type="checkbox"/>	<input type="checkbox"/>	2 nights

Date of Arrival: (DD/MM/YY) Date of Departure: (DD/MM/YY)
= Total Number of Nights: ☐ Late Arrival (approximately: h)
Sharing with (in case you have chosen a double room):
Special requests:

C. CANCELLATION POLICY / TERMS & CONDITIONS

Hotelbooking: Prices are per room per night incl. breakfast, service charges and taxes. The number of nights booked serves as a basis for your hotel invoice. Should the desired hotel category no longer be available, similar accommodation will be offered. Please note, the hotel booking can only be guaranteed upon receipt of the respective hotel deposit (two nights). All changes or cancellations must be made in writing. Due to organisational reasons we would kindly ask you to make your room reservation till February 17, 2012. Cancellations of rooms received before December 15, 2011 will be refunded, less an administration fee of EUR 50,00. For cancellations received after December 15, 2011 or no-shows the deposit will not be refunded. Rates are in EUR and include VAT. In case new statutory levies are introduced, these will be added to the price.

D. MODE OF PAYMENT

☐ Bank Transfer to account "Mondial Congress & Events"

IBAN code: AT11 1200 0529 4602 6888 SWIFT / BIC code: BKAUATWW
Accountnr. 52946026888 at UniCredit Bank Austria AG, Schottengasse 6-8, 1010 Vienna (Austria)
Routing code: 12000 Account owner: Mondial GmbH & Co. KG

Please instruct your bank to carry out the transactions "Free of charge for the recipient".
Any bank fees incurred will be charged to the respective participant.

☐ Please charge the following credit card (Visa, Eurocard/Mastercard, Amex and Diners will be accepted)

☐ VISA ☐ Eurocard / Mastercard ☐ Diners Club ☐ Amex
Card number:
Expiry date:
Cardholders name:
Cardholders signature:

F. LIABILITY

Mondial GmbH & Co. KG shall act as mediator only and cannot be held responsible for any loss incurred or any damage inflicted on persons or objects irrespective of whatsoever cause. The liability for transport- and other service companies shall not be effected by the above. Only written agreements shall be valid. The place of jurisdiction shall be Vienna.

Place

Date Signature

Please choose your hotel from the following list:

Hotel	Category	Price Double Room Single Use	Price Double Room	Distance to Congress Venue by public transportation
De France	no cat.	240	215	25 min
Grand Hotel	5	350	310	20 min
Radisson BLU Palais Hotel	5	289	264	25 min
Radisson BLU Style Hotel	no cat.	268	253	30 min
Sacher	5	379	349	20 min
The Ring	5	305	265	20 min
Ananas	4	150	135	30 min
Arcotel Kaiserwasser	4	199	179	8 min
Astoria	4	190	175	20 min
Capricorno	4	168	146	20 min
Courtyard by Marriott Wien Messe	no cat.	241	223	25 min
Das Triest	no cat.	220	190	25 min
Donauzentrum	4	160	145	20 min
Europa	4	190	175	20 min
Favorita	4	150	135	30 min
Am Konzerthaus (by Gallery)	4	163	146	30 min
InterCityHotel	4	167	143	30 min
Lassalle	4	160	145	20 min
Lindner Hotel am Belvedere	4	229	189	30 min
Mercure GH Biedermeier Wien	4	163	146	30 min
Mercure Wien City	4	159	144	25 min
Mercure Wien Europaplatz	4	139	124	35 min
Mercure Wien Westbahnhof	4	139	124	35 min
NH Danube City	4	200	180	15 min
Novotel Wien City	4	183	166	20 min
Park Inn Vienna	4	175	160	10 min
Rainers Hotel	4	210	190	35 min
Rathauspark	4	180	165	30 min
Roomz Vienna	no cat.	150	140	35 min
Art Hotel Vienna	3	123	108	40 min
Capri	3	140	119	20 min
Fürst Metternich	3	167	136	30 min
Am Augarten	3	145	125	25 min
Beim Theresianum	3	140	125	25 min
Drei Kronen	3	129	119	25 min
Ibis Wien Mariahilf	3	113	85	35 min
Ibis Wien Messe	3	113	85	20 min
Messe Wien	3	160	145	25 min
Post	3	108	94	20 min
Senator Hotel	3	163	143	40 min
Suite Novotel Wien Messe	no cat.	143	131	15 min
Wandl	3	170	140	20 min
Austria Classic Hotel Wien	3	149	149	20 min

CONFERENCE NEWSPAPER

EBCC-8: *The Bulletin* is the official newspaper of the 8th European Breast Cancer Conference - an enjoyable must-read for all participants with up-to-the-minute news, features, reports, interviews and next day highlights.

The first issue will be available on the first day of the Conference, 21 March 2012 and the second on 22 March 2012, followed by extra features, highlights and news online on 23 March. Each edition will also be published at: www.ecco-org.eu.

EXHIBITION

The EBCC-8 Exhibition represents an essential and integral element of the Conference, providing participants with an excellent platform for networking as well as perfect opportunity to gain further insight into cutting edge technology, latest healthcare solutions and services within the breast cancer field.

The Organising Committee would like to thank and acknowledge the 8th European Breast Cancer Conference partners for their support and shared insight. For latest list of exhibitors, the Exhibition info and detailed floor plans please visit: www.ecco-org.eu ('Conferences and conferences', 'EBCC 8', 'Exhibition/Sponsorship').

Entrance to the Exhibition is free for all registered participants. The Exhibition will be open as follows:

Wednesday 21 March 2012	12:00 - 18:30
Thursday 22 March 2012	10:00 - 16:30
Friday 23 March 2012	10:00 - 14:00

Companies, publishers and organisations that would like to participate in the exhibition can download the 'Invitation to Industry' from the Conference website at: www.ecco-org.eu, or contact Bruno De Man via e-mail: bruno.deman@ecco-org.eu, or Tel: +32 (2) 775 02 04.

INSURANCE

The organisers do not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements regarding health and travel insurance.

LANGUAGE AND TRANSLATION

The official language of the Conference is English. No simultaneous translation will be provided.

For additional information please contact:
The EBCC-8 Congress Secretariat
c / o ECCO – the European CanCer Organisation

Avenue E. Mounier 83
B-1200 Brussels
Belgium
Tel: +32 2 775 02 01
Fax: +32 2 775 02 00
e-mail: ebcc8@ecco-org.eu
Website: www.ecco-org.eu



www.ecco-org.eu



SAVE UP TO 20% ON GETTING TO YOUR CONVENTION WITH CONVENTIONS PLUS

It's easy to save money on your flights if you fly the Star Alliance™ network. Simply quote the event code SK04A23 when you make your booking with any Star Alliance member airline and you'll automatically get a discount of up to 20%.

The Star Alliance network has 27 member airlines with over 21,000 flights a day so we can offer you a lot more choice when planning your travel. For more information about our member airlines and contact details, please visit our website at www.staralliance.com/conventionsplus

ADRIA

AEGEAN

AIR CANADA

AIR CHINA

AIR NEW ZEALAND

ANA

ASIANA AIRLINES

Austrian

Blue

British Midland International

brussels airlines

Continental Airlines

CROATIA AIRLINES

EGYPTAIR

LOT POLISH AIRLINES

Lufthansa

Scandinavian Airlines

SINGAPORE AIRLINES

SOUTH AFRICAN AIRWAYS

Spanair

SWISS

TAM

TAP PORTUGAL

THAI

TURKISH AIRLINES

UNITED

U.S. AIRWAYS

www.staralliance.com

Information correct as at 09/2010

STAR ALLIANCE
THE WAY THE EARTH CONNECTS





CHEMO? NO CHEMO?

The Oncotype DX[®] Breast Cancer Assay helps you find an answer

Oncotype DX provides further insight into the **underlying tumor biology** of breast cancer

- Validated through an extensive suite of studies, across a continuum of more than 4,000 ER-positive patients in 13 clinical studies¹⁻¹³
- Validating the assay prospectively using archived samples meets the description of level 1b evidence as described in Simon et al., 2009¹⁴
- Provides accurate information and precision with a 97 % success rate¹⁵
- Since 2004, over 10,000 physicians in 60+ countries have ordered more than 200,000 Oncotype DX tests

STUDY	TYPE	NO. PTS	REFERENCE
Providence	Exploratory	136	1. Esteban et al. ASCO 2003: abstr 3416
Rush	Exploratory	78	2. Cobleigh et al. CCR 2005
NSABP B-20	Exploratory	233	3. Paik et al. SABCS 2003: abstr 16
NSABP B-14	Prospective	668	4. Paik et al. NEJM 2004
MD Anderson	Prospective	149	5. Esteva et al. CCR 2005
Kaiser Permanente	Prospective case-control	790 cases/controls	6. Habel et al. BCR 2006
NSABP B-14	Prospective placebo vs Tam	645	7. Paik et al. SABCS 2004: abstr 24
INT-Milan	Exploratory neoadjuvant	89	8. Gianni et al. JCO 2005
NSABP B-20	Prospective Tam vs Tam+Chemo	651	9. Paik et al. JCO 2006
ECOG 2197	Exploratory and prospective	776	10. Goldstein et al. JCO 2007
SWOG 8814	Prospective Tam vs Tam+Chemo	367	11. Albain et al. Lancet Oncol 2010
transATAC	Prospective Tam vs AI	1231	12. Dowsett et al. JCO 2010
JBCRG study	Prospective	280	13. Toi et al. Cancer 2010

Visit us at www.oncotypedx.com for information on how to order Oncotype DX

14. Simon RM, et al. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101(21):1446-1452. 15. Anderson JM, Shak S, Millward C, et al. Molecular characterization of breast cancer core biopsy specimens by gene expression analysis using standardized quantitative RT-PCR. Poster presented at: 32nd Annual San Antonio Breast Cancer Symposium; December 2009; San Antonio, TX. Poster 6021.



Genomic Health, Oncotype DX, and Recurrence Score[®] are registered trademarks of Genomic Health, Inc.
©2010 Genomic Health, Inc. All rights reserved. INT-503-E-01/11 v1

oncotype DX[®]
Breast Cancer Assay